ClinicalTrials.Veeva

Menu
T

The Retina Clinic London | London, United Kingdom

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

JNJ-81201887
GT005

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 5 total trials
Locations recently updated

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been tr...

Invitation-only
Age Related Macular Degeneration (AMD)
Genetic: GT005

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: ABBV-RGX-314 Dose 1
Biological: Aflibercept (EYLEA®)

Trial sponsors

G
Janssen (J&J Innovative Medicine) logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems